Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir Open-Label Access for HIV Patients with Integrase Resistance
2011-001646-16Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Safety (serious adverse events) and Safety (AEs leading to dolutegravir discontinuation). Started Aug 2012; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-001646-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001646-16.